---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-107390"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:36:13.791772+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development

## Summary
- Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.
- Cash, equivalents & restricted cash $39.8M; plus $36.3M in NIH grant funds; runway into Q2 2027.
- Closed $30M registered direct offering of 14.7M shares to institutional investors.
- FDA aligned on registrational path for zervimesine (CT1812) in Alzheimer's disease.
- Phase 2 START study >75% enrolled; expanded access program for dementia with Lewy bodies ongoing.

## SEC filing metadata
- accession: 0001104659-25-107390
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/0001104659-25-107390-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925107390/tm2530237d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-107390
- JSON: https://secwatch.observer/filing/0001104659-25-107390.json
- Plain text: https://secwatch.observer/filing/0001104659-25-107390.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.